CN100553671C - 一种治疗脂肪肝的中药 - Google Patents
一种治疗脂肪肝的中药 Download PDFInfo
- Publication number
- CN100553671C CN100553671C CNB2006100704734A CN200610070473A CN100553671C CN 100553671 C CN100553671 C CN 100553671C CN B2006100704734 A CNB2006100704734 A CN B2006100704734A CN 200610070473 A CN200610070473 A CN 200610070473A CN 100553671 C CN100553671 C CN 100553671C
- Authority
- CN
- China
- Prior art keywords
- liver
- chinese medicine
- fatty liver
- traditional chinese
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 13
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 13
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 13
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims description 22
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 2
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 2
- 240000001851 Artemisia dracunculus Species 0.000 abstract 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 2
- 244000077995 Coix lacryma jobi Species 0.000 abstract 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 2
- 244000046146 Pueraria lobata Species 0.000 abstract 2
- 239000001138 artemisia absinthium Substances 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及治疗肝病的中药,一种治疗脂肪肝的中药,采用茵陈、决明子、山楂、黄芪、生薏苡仁、葛根、泽泻原料制备而成,是由下列重量百分比的组分组成:茵陈11-19%、决明子17-23%、山楂12-18%、黄芪12-18%、生薏苡仁8-12%、葛根8-12%、泽泻12-18%。本发明提供的组方原料成本低,能平肝健脾,利湿化痰,导滞活血,具有调整血脂,促进肝细胞修复之功,治疗脂肪肝效果好,无毒副作用。
Description
技术领域
本发明涉及一种治疗肝病的中药,具体地说是一种治疗脂肪肝的中药。
背景技术
随着人们生活水平的提高,饮食习惯及生活方式的改变,脂肪肝的发病也越来越多,呈逐年上升的趋势,已成为临床常见病、多发病。如治疗不及时,肝脏损害将进一步加重,易出现肝硬化病变。目前对此病的治疗,一般在控制饮食及适当运动的基础上,采用西药他汀类或贝特类降脂药物,且降脂药物还有损害肝细胞的副作用,疗效不理想,还易复发。
发明内容
本发明的目的是解决上述现有技术的不足,提供一种无毒副作用,具有疗效显著,不反弹的治疗脂肪肝的中药。
本发明解决上述技术问题采取的技术方案是:一种治疗脂肪肝的中药,其特征在于是采用茵陈、决明子、山楂、黄芪、生薏苡仁、葛根、泽泻原料制备而成,由下列重量百分比的组分组成:茵陈11-19%、决明子17-23%、山楂12-18%、黄芪12-18%、生薏苡仁8-12%、葛根8-12%、泽泻12-18%。将茵陈、决明子、山楂、黄芪、生薏苡仁、葛根、泽泻洗净后,用水浸泡,然后煎熬,去渣得滤液,灭菌经提炼后制得药剂或精选洗净晾干后极细面,常规高压灭菌,炼制为丸剂。
本发明组分中的茵陈、泽泻:清热,利水渗湿;决明子:养阴平肝,利尿降压;山楂:消食导滞,活血化瘀;黄芪、生薏苡仁:补气健脾,燥湿,气行则血行;葛根:生津制燥,升发阳气。现代药理学研究证明:茵陈、泽泻、决明子有明显的保肝调脂作用;山楂、黄芪、生薏苡仁、葛根均能使血清胆固醇、甘油三脂、低密度脂蛋白下降,高密度脂蛋白升高。
本发明提供的组方原料成本低,能平肝健脾,利湿化痰,导滞活血,具有调整血脂,促进肝细胞修复之功,治疗脂肪肝效果好,无毒副作用。
具体实施方式
实施例1:一种治疗脂肪肝的中药,采用茵陈、决明子、山楂、黄芪、生薏苡仁、葛根、泽泻原料制备而成,其组成为重量百分比茵陈15、决明子23、山楂15、黄芪14、生薏苡仁12、葛根8、泽泻13。在室温条件下,取上述七种原料总重量50千克,精选洗净后,用20000ml水浸泡2-4小时,然后煎熬45分钟左右,用常规方法经过去渣过滤、高压、灭菌工艺后,制取药剂。药剂的服用方法:每次150ml,早晚二次服用,20天为一个疗程,每个疗程间隔3天,连续服用四个疗程。
实施例2:一种治疗脂肪肝的中药,采用茵陈、决明子、山楂、黄芪、生薏苡仁、葛根、泽泻原料制备而成,其组成为重量百分比茵陈14、决明子21、山楂18、黄芪15、生薏苡仁11、葛根9、泽泻12。丸剂的制取是:上述七种原料总重量54千克,精选洗净晾干后研磨极细面,用常规方法高压灭菌,炼制为水丸,每丸重约9克。丸剂服用方法,每次1丸,早晚二次服用,20天为一个疗程,每个疗程间隔3天,连续服用四个疗程。
实施例 | 茵陈 | 决明子 | 山楂 | 黄芪 | 生薏苡仁 | 葛根 | 泽泻 |
实施例3 | 13 | 22 | 17 | 14 | 8 | 11 | 15 |
实施例4 | 17 | 19 | 14 | 16 | 10 | 10 | 14 |
实施例5 | 16 | 17 | 13 | 17 | 9 | 12 | 16 |
病例选择:
临床随机选择68例患者,男38例,女30例,年龄40-65岁;病程最短3个月,最长10年;体形肥胖52例,嗜酒史29例,高血压病史12例,冠心病史16例。
诊断标准:
(1)西医诊断标准参照叶维法主编≤临床肝胆病学≥中的脂肪肝诊断标准。
(2)中医诊断标准参照国家中医药管理局发布的≤中医病症诊断疗效标准≥,分为气虚型15例,肝郁气滞型8例,肝胆湿热型16例,肾阴不足型9例,阴虚阳亢型8例,痰淤交阻型12例。多数患者不同程度出现神疲乏力,脘腹痞满,食欲不振,倦怠懒言,肝区不适,大便溏薄,舌质暗苔厚腻。
疗效判断:
临床治愈:临床症状及体征消失,B超检查肝胆形态结构正常,实验室检查正常。
显效:临床症状及体征消失,B超检查肝胆形态结构基本恢复正常,实验室检查较治疗前明显改善。
有效:临床症状减轻,B超及实验室检查较治疗前明显有改善。
无效:临床症状B超及实验室检查无改变。
治疗效果:使用本发明治疗68例,四个疗程,结果临床治愈32例,占47.1%,显效20例,占29.4%,有效11例,占16.2%,无效5例,占7.4%,总有效率92.75%。
Claims (1)
1、一种治疗脂肪肝的中药,其特征在于是由下列重量百分比的原料制成:茵陈11-19%、决明子17-23%、山楂12-18%、黄芪12-18%、生薏苡仁8-12%、葛根8-12%、泽泻12-18%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100704734A CN100553671C (zh) | 2006-11-29 | 2006-11-29 | 一种治疗脂肪肝的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100704734A CN100553671C (zh) | 2006-11-29 | 2006-11-29 | 一种治疗脂肪肝的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1970031A CN1970031A (zh) | 2007-05-30 |
CN100553671C true CN100553671C (zh) | 2009-10-28 |
Family
ID=38111179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100704734A Expired - Fee Related CN100553671C (zh) | 2006-11-29 | 2006-11-29 | 一种治疗脂肪肝的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100553671C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110898180A (zh) * | 2019-12-17 | 2020-03-24 | 湖南橘色科技有限责任公司 | 一种活血降脂减肥组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850217A (zh) * | 2006-01-28 | 2006-10-25 | 吉林敖东药业集团延吉股份有限公司 | 一种用于治疗脂肪肝的复方制剂及制备方法 |
-
2006
- 2006-11-29 CN CNB2006100704734A patent/CN100553671C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850217A (zh) * | 2006-01-28 | 2006-10-25 | 吉林敖东药业集团延吉股份有限公司 | 一种用于治疗脂肪肝的复方制剂及制备方法 |
Non-Patent Citations (1)
Title |
---|
《中药学》. 贺兴东等,第442-443页,学苑出版社. 1998 * |
Also Published As
Publication number | Publication date |
---|---|
CN1970031A (zh) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102441081B (zh) | 一种治疗痛风病的药物及其制备方法 | |
CN101062377B (zh) | 一种通经活络、祛风散寒、消炎止痛的膏药 | |
CN102188685B (zh) | 一种治疗腹泻型肠易激综合征的中药外敷散剂及其制备方法 | |
CN102727736A (zh) | 一种治疗便秘的药物 | |
CN101569699B (zh) | 一种治疗前列腺炎的药物组合物及其制备方法 | |
CN103211930A (zh) | 一种降血脂、降血压的中药制剂 | |
CN100579562C (zh) | 一种内服治疗便秘的中药组合物 | |
CN102000238B (zh) | 九龙胶囊及制备方法 | |
CN100553671C (zh) | 一种治疗脂肪肝的中药 | |
CN102671056B (zh) | 一种治疗肝炎的中药组合物及其制备方法 | |
CN102641471B (zh) | 一种治疗胆结石的中药 | |
CN102935214B (zh) | 一种治疗尿毒症的中药组合物 | |
CN101700390A (zh) | 一种内服治疗脂肪肝的中药组合物 | |
CN104288392A (zh) | 一种用于治疗动脉硬化的中药 | |
CN101028503B (zh) | 一种内服治疗雷诺氏症的中药组合物 | |
CN116370592B (zh) | 治疗非酒精性脂肪性肝纤维化的中药组合物及其制备方法和应用 | |
CN103656277B (zh) | 治疗肝腹水的药物 | |
CN102631481B (zh) | 一种治疗病毒性肝炎的中药制剂 | |
CN102335399B (zh) | 一种治疗早期肝硬化的中药组合物 | |
CN102335398A (zh) | 一种治疗高脂血症的中药配方 | |
CN102641441B (zh) | 一种治疗多痰症的中药 | |
CN101347573B (zh) | 一种治疗肝硬化腹水、肝肾综合症的药物及其制备方法 | |
CN104189435A (zh) | 一种治疗痰热互结型梅核气的中药 | |
CN101371908A (zh) | 一种防治体内结石的胶丸 | |
CN101810740B (zh) | 一种治疗脑萎缩的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091028 Termination date: 20101129 |